Literature DB >> 30303693

The impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal and metabolic parameters in lean women with polycystic ovary syndrome.

Gokce Anik Ilhan1, Begum Yildizhan1, Tanju Pekin1.   

Abstract

This study was performed to assess the impact of lipid accumulation product (LAP) and visceral adiposity index (VAI) on clinical, hormonal, and metabolic parameters in lean women with PCOS. Retrospective analysis of 120 consecutive lean PCOS subjects was performed. Subjects were divided into two groups according to HOMA-IR, as IR + and IR-. A HOMA-IR value above 2.5 was used to indicate IR. Clinical, hormonal and metabolic parameters were compared between the two groups. Correlations between LAP and VAI and clinical, hormonal, metabolic features in women PCOS were analyzed. One hundred twenty lean PCOS subjects were enrolled, of which 39 were insulin resistant. Comparison of group means showed significantly higher values for TG levels, FAI, FGS, TG/HDL-c, TyG, LAP, and VAI indexes and lower values for glucose/insulin ratio and QUICKI in the IR + group. LAP and VAI were both found to be positively correlated with each other and with WC, FAI, FGS, TG, TC levels, lipid ratios, TyG index, and HOMA-IR and negatively correlated with Glucose/Insulin ratio, QUICKI, and HDL-c in lean women with PCOS. LAP and VAI may be promising in early identification of IR and cardiometabolic risk and may be useful for the assessment of hyperandrogenism in lean women with PCOS.

Entities:  

Keywords:  Polycystic ovary syndrome; insulin resistance; lean; lipid accumulation product; visceral adiposity index

Mesh:

Substances:

Year:  2018        PMID: 30303693     DOI: 10.1080/09513590.2018.1519794

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  6 in total

1.  Endocrine-Metabolic Dysfunction in Polycystic Ovary Syndrome: an Evolutionary Perspective.

Authors:  Daniel A Dumesic; David H Abbott; Smriti Sanchita; Gregorio D Chazenbalk
Journal:  Curr Opin Endocr Metab Res       Date:  2020-03-09

2.  Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Julia D Phan; Karen L Leung; Tristan R Grogan; Xiangmiang Ding; Xinmin Li; Luis R Hoyos; David H Abbott; Gregorio D Chazenbalk
Journal:  J Clin Endocrinol Metab       Date:  2019-06-01       Impact factor: 5.958

3.  Lipid accumulation product independently correlate with hepatic steatosis quantified by controlled attenuation parameter in women with polycystic ovary syndrome.

Authors:  Silan Zheng; Meifeng Tong; Lianqin Dong; Chunmin Du; Xin Zheng; Liying Wang; Peiying Huang; Wei Liu; Mingzhu Lin; Changqin Liu
Journal:  Endocr Connect       Date:  2020-02       Impact factor: 3.335

4.  The Prevalence of Polycystic Ovary Syndrome, Its Phenotypes and Cardio-Metabolic Features in a Community Sample of Iranian Population: Tehran Lipid and Glucose Study.

Authors:  Mahbanoo Farhadi-Azar; Samira Behboudi-Gandevani; Maryam Rahmati; Fatemeh Mahboobifard; Ensi Khalili Pouya; Fahimeh Ramezani Tehrani; Fereidoun Azizi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-01       Impact factor: 5.555

5.  The relation between visceral fat markers and cardiometabolic disease risks in psoriasis patients.

Authors:  Arzu Ataseven; Ruhusen Kutlu; Latife Uzun
Journal:  North Clin Istanb       Date:  2021-05-24

6.  Lipid Accumulation Product Is More Related to Insulin Resistance than the Visceral Adiposity Index in the Maracaibo City Population, Venezuela.

Authors:  Valmore Bermúdez; Juan Salazar; Jorge Fuenmayor; Manuel Nava; Ángel Ortega; Pablo Duran; Milagros Rojas; Roberto Añez; Alejandra Rivas-Montenegro; Lissé Angarita; Maricarmen Chacín; Clímaco Cano; Manuel Velasco; Joselyn Rojas
Journal:  J Obes       Date:  2021-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.